Trials / Recruiting
RecruitingNCT06314373
A Study for HSK39775 in Participants With Solid Tumors
A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 243 (estimated)
- Sponsor
- Xizang Haisco Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK39775 Monotherapy | HSK39775 will be administered orally once daily |
Timeline
- Start date
- 2024-03-07
- Primary completion
- 2028-02-01
- Completion
- 2028-09-01
- First posted
- 2024-03-18
- Last updated
- 2024-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06314373. Inclusion in this directory is not an endorsement.